Suzhou Connect Biopharmaceuticals - About the company
Suzhou Connect Biopharmaceuticals is a public company based in Suzhou (China), founded in 2012 by William Pan and Zheng Wei. It operates as a Discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Suzhou Connect Biopharmaceuticals has raised $195M in funding from investors like RA Capital Management, Qiming Venture Partners and Cowin Capital. The company has 425 active competitors, including 139 funded and 116 that have exited. Its top competitors include companies like BeiGene, Biogen and argenx.
Company Details
Discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its lead drug CBP-307, a selective second-generation S1P1 (a G-protein coupled receptor -GPCR) modulator is being developed for the treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease, and psoriasis
- Website
- connectbiopharm.com
- Email ID
- *****@connectpharm.com
- Phone Number
- +86 **********
Key Metrics
Founded Year
2012
Location
Suzhou, China
Stage
Public
Total Funding
$195M in 4 rounds
Latest Funding Round
Investors
Ranked
41st among 425 active competitors
Employee Count
62 as on Dec 31, 2024
Exit Details
Public
Suzhou Connect Biopharmaceuticals's IPO details
Suzhou Connect Biopharmaceuticals got listed on Mar 19, 2021.
Click here to take a look at Suzhou Connect Biopharmaceuticals's IPO in detail
Sign up to download Suzhou Connect Biopharmaceuticals' company profile
Suzhou Connect Biopharmaceuticals's funding and investors
Suzhou Connect Biopharmaceuticals has raised a total funding of $195M over 4 rounds. Its latest funding round was a Series C round on Aug 24, 2020 for $*****. 5 investors participated in its latest round. Suzhou Connect Biopharmaceuticals has 12 institutional investors.
Here is the list of recent funding rounds of Suzhou Connect Biopharmaceuticals:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 24, 2020 | 8663577 | Series C | 8464475 | 9005275 | 2342592 | 5458581 |
Jan 02, 2019 | 6440022 | Series B | 1741766 | 7400174 | 4380387 | |
Jan 24, 2017 | 2812853 | Series A | 2156683 | 8281166 |
Access funding benchmarks and valuations. Sign up today!View details of Suzhou Connect Biopharmaceuticals's funding rounds and investors
Suzhou Connect Biopharmaceuticals' founders and board of directors
Founder? Claim ProfileThe founders of Suzhou Connect Biopharmaceuticals are William Pan and Zheng Wei. Zheng Wei is the CEO of Suzhou Connect Biopharmaceuticals.
Here are the details of Suzhou Connect Biopharmaceuticals' key team members:
- William Pan: Co-Founder & President of Suzhou Connect Biopharmaceuticals.
- Zheng Wei: Co-Founder & CEO of Suzhou Connect Biopharmaceuticals.
Suzhou Connect Biopharmaceuticals' employee count trend
Suzhou Connect Biopharmaceuticals has 62 employees as of Dec 24. Here is Suzhou Connect Biopharmaceuticals's employee count trend over the years:
Uncover Suzhou Connect Biopharmaceuticals' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Suzhou Connect Biopharmaceuticals's Competitors and alternates
Top competitors of Suzhou Connect Biopharmaceuticals include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Suzhou Connect Biopharmaceuticals, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
2nd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
4th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
5th |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 71/100 | |
6th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 69/100 | ||
7th | Immunocore 2008, Abingdon (United Kingdom), Public | Developer of bispecific T cell receptor therapies for human diseases | $601M | 69/100 | |
8th | ADMA Biologics 2005, Ramsey (United States), Public | Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases | $17.6M | 68/100 | |
9th |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
10th | DBV Technologies 2002, Bagneux (France), Public | Developer of products for the treatment of various kinds of food allergies | $68.9M | 68/100 | |
41st | Suzhou Connect Biopharmaceuticals 2012, Suzhou (China), Public | Discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation | $195M | 54/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Suzhou Connect Biopharmaceuticals's competitors? Click here to see the top ones
Suzhou Connect Biopharmaceuticals's Investments and acquisitions
Suzhou Connect Biopharmaceuticals has made no investments or acquisitions yet.
Reports related to Suzhou Connect Biopharmaceuticals
Here is the latest report on Suzhou Connect Biopharmaceuticals's sector:
News related to Suzhou Connect Biopharmaceuticals
Filter this listMedia has covered Suzhou Connect Biopharmaceuticals for 1 event in last 1 year.
•
•
•
Connect Biopharma Appoints Jim Schoeneck to its Board of DirectorsGlobeNewswire•Jul 22, 2025•Suzhou Connect Biopharmaceuticals
•
•
•
Connect Biopharma Presents Rademikibart Data at EAACI 2025 CongressGlobeNewswire•Jun 13, 2025•Suzhou Connect Biopharmaceuticals
•
Connect Biopharma files $300M mixed securities shelfSeeking Alpha•Jun 10, 2025•Suzhou Connect Biopharmaceuticals
•
•
•
Connect Biopharma Reports 2024 Full-Year Financial ResultsGlobeNewswire•Mar 31, 2025•Suzhou Connect Biopharmaceuticals
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Suzhou Connect Biopharmaceuticals
Explore our recently published companies
- biogrid as - Oslo based, 2015 founded, Unfunded company
- Givers - Palm Beach Gardens based, 2021 founded, Funding Raised company
- WALDEN OAKS PRESERVATION - Funding Raised company
- CATHBUDDY - Funding Raised company
- IMPLENOMICS - Funding Raised company
- RHEINISCHE FRIEDRICHWILHELMSUNIVERSITAET BONN - Funding Raised company
